Sun Pharma Resolves US Antitrust Lawsuit with USD 200 Million Settlement
Sun Pharmaceutical Industries has agreed to a USD 200 million settlement to resolve an antitrust litigation in the US. The settlement involves Sun's subsidiaries, who have signed an agreement with plaintiffs in a pricing case in Pennsylvania. The deal awaits court approval and may adjust based on class member actions.
- Country:
- India
Sun Pharmaceutical Industries has announced a significant settlement to conclude an antitrust lawsuit in the United States, agreeing to pay USD 200 million.
The Mumbai-based firm confirmed in a regulatory filing that its subsidiaries, Sun Pharmaceutical Industries, Inc. (SPII) and Taro Pharmaceuticals USA, Inc., have entered into an agreement with the End Purchaser Plaintiffs in the case concerning generic pharmaceuticals pricing in the Eastern District of Pennsylvania.
The settlement terms include a collective payment of USD 200 million for a full release of claims against them by the class members. The agreement, pending court approval, may see a reduction in settlement amounts if a certain percentage of the insured class opts out.
(With inputs from agencies.)
Google News